SCHEMBL23828404

SCHEMBL23828404

Cc1nc2cc(Cl)nc(-c3ccc(C)o3)n2n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 5/20 0.36
ALDH1A1 P00352 5/20 0.36
MAPT P10636 5/20 0.36
KDM4E B2RXH2 4/20 0.36
HPGD P15428 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
ADORA2A P29274 2/20 0.36
LMNA P02545 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
PKLR P30613 2/20 0.35
PDE5A O76074 1/20 0.34
GAA P10253 5/20 0.33
TP53 P04637 2/20 0.33
GFER P55789 1/20 0.33
PDE10A Q9Y233 1/20 0.32
HSF1 Q00613 1/20 0.32
POLB P06746 1/20 0.32
RECQL P46063 1/20 0.32
KDM5B Q9UGL1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23828464 0.82 ADORA2A (0.41) PKMALDH1A1MAPTKDM4EHPGD
SCHEMBL22941862 0.78 NPC1 (0.40) PKMALDH1A1MAPTKDM4EHPGD
SCHEMBL25331904 0.77 ADORA2A (0.40) PKMALDH1A1MAPTKDM4EHPGD
SCHEMBL25330773 0.77 ADORA2A (0.42) ALDH1A1MAPTKDM4ESMN1; SMN2ADORA2A
SCHEMBL30507583 0.76 ALDH1A1 (0.42) PKMALDH1A1MAPTKDM4EHPGD
SCHEMBL23828492 0.75 NOTUM (0.35) PKMLMNA
SCHEMBL23828390 0.75 PIK3CG (0.46) ALDH1A1KDM4ESMN1; SMN2ADORA2A
SCHEMBL23846002 0.74 LMNA (0.44) ALDH1A1MAPTKDM4EHPGDSMN1; SMN2
SCHEMBL23828432 0.73 KDM4E (0.37) PKMALDH1A1MAPTKDM4EHPGD
SCHEMBL30507608 0.72 PDE10A (0.37) PKMALDH1A1MAPTKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12264161-B2 Heterocyclic adenosine receptor antagonists EXELIXIS, INC. (US) 2025-04-01 US disclosed
US-20230382917-A1 Heterocyclic Adenosine Receptor Antagonists EXELIXIS, INC. 2023-11-30 US disclosed
US-20230382917-A1 Heterocyclic Adenosine Receptor Antagonists EXELIXIS, INC. 2023-11-30 US disclosed
US-20230382917-A1 Heterocyclic Adenosine Receptor Antagonists EXELIXIS, INC. 2023-11-30 US disclosed
US-11718622-B2 Heterocyclic adenosine receptor antagonists EXELIXIS INC. (US) 2023-08-08 US disclosed
US-11718622-B2 Heterocyclic adenosine receptor antagonists EXELIXIS INC. (US) 2023-08-08 US disclosed
US-11718622-B2 Heterocyclic adenosine receptor antagonists EXELIXIS INC. (US) 2023-08-08 US disclosed
US-20210292332-A1 Heterocyclic Adenosine Receptor Antagonists EXELIXIS, INC. 2021-09-23 US disclosed
US-20210292332-A1 Heterocyclic Adenosine Receptor Antagonists EXELIXIS, INC. 2021-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292332-A1 Heterocyclic Adenosine Receptor Antagonists ADORA2A, ADORA1, ADORA3 PKM 3177/4885ALDH1A1 789/4885MAPT 4801/4885
US-20230382917-A1 Heterocyclic Adenosine Receptor Antagonists ADORA2A, ADORA1, ADORA3 PKM 3177/4885ALDH1A1 789/4885MAPT 4801/4885
US-11718622-B2 Heterocyclic adenosine receptor antagonists ADORA2A, ADORA1, ADORA3 PKM 3177/4885ALDH1A1 789/4885MAPT 4801/4885
US-12264161-B2 Heterocyclic adenosine receptor antagonists ADORA2A, ADORA1, ADORA3 PKM 3177/4885ALDH1A1 789/4885MAPT 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.